These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 29718013)

  • 1. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine for Major Depressive Disorder.
    Costi S
    Curr Top Behav Neurosci; 2024; 66():131-147. PubMed ID: 37922100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

  • 5. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
    Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
    Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 7. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine: The final frontier or another depressing end?
    Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
    Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2018 Oct; 56(10):11-14. PubMed ID: 30278095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of ketamine.
    Stahl SM
    CNS Spectr; 2013 Aug; 18(4):171-4. PubMed ID: 23866089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ketamine--a new treatment option for therapy-resistant depression].
    Köhler S; Betzler F
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine-induced affective switch in a patient with treatment-resistant depression.
    Banwari G; Desai P; Patidar P
    Indian J Pharmacol; 2015; 47(4):454-5. PubMed ID: 26288483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How does ketamine elicit a rapid antidepressant response?
    Kavalali ET; Monteggia LM
    Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.